Literature DB >> 35760922

Vascular involvement and resectability of pancreatic ductal adenocarcinoma on contrast-enhanced MRI: comparison with pancreatic protocol CT.

Yoshifumi Noda1, Nobuyuki Kawai2, Tetsuro Kaga2, Takuma Ishihara3, Fuminori Hyodo4, Hiroki Kato2, Avinash R Kambadakone5, Masayuki Matsuo2.   

Abstract

PURPOSE: To compare the diagnostic performance for detecting vascular involvement and determining resectability differences regarding pancreatic ductal adenocarcinoma (PDAC) between contrast-enhanced CT and MRI.
METHODS: This retrospective study evaluated 82 patients (73 years, 46 men) with PDAC who underwent both preoperative contrast-enhanced CT and MRI from January 2008 to March 2021. Two radiologists independently categorized vascular involvements for celiac, superior mesenteric, splenic, and common hepatic arteries, and portal, superior mesenteric, and splenic veins into no tumor contact, solid soft-tissue contact ≤ 180°, or solid soft-tissue contact > 180°. The radiologists also classified resectability into resectable, borderline resectable, or locally advanced. Receiver-operating-characteristic (ROC) analysis was conducted to evaluate the diagnostic performances for detecting vascular involvements which were confirmed by pathological or intraoperative findings. The proportion of resectability classifications was compared between CT and MRI by the Fisher's exact test.
RESULTS: No statistical difference was found in the diagnostic performances for detecting vascular involvement in CT (area under the ROC curve [AUC], 0.50-0.89) and MRI (AUC, 0.51-0.75) (P = 0.06-> 0.99). Resectability on CT were 79% and 68%, 20% and 26%, and 1% and 6% for resectable, borderline resectable, and locally advanced tumors for reviewers 1 and 2; those on MRI were 87% and 81%, 12% and 13%, and 1% and 6%, respectively. The proportion of resectability classifications was not different between CT and MRI (P = 0.48 and = 0.15 for reviewers 1 and 2, respectively).
CONCLUSION: The diagnostic performance for detecting vascular involvement and determining resectability of PDAC on contrast-enhanced MRI were comparable with pancreatic protocol CT.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Magnetic resonance imaging; Multidetector computed tomography; Pancreas

Mesh:

Year:  2022        PMID: 35760922     DOI: 10.1007/s00261-022-03581-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  2 in total

1.  Ovarian cancer reporting lexicon for computed tomography (CT) and magnetic resonance (MR) imaging developed by the SAR Uterine and Ovarian Cancer Disease-Focused Panel and the ESUR Female Pelvic Imaging Working Group.

Authors:  Elizabeth A Sadowski; Atul B Shinagare; Hyesun Park; Olga R Brook; Rosemarie Forstner; Sumer K Wallace; Jeanne M Horowitz; Neil Horowitz; Marcia Javitt; Priyanka Jha; Aki Kido; Yulia Lakhman; Susanna I Lee; Lucia Manganaro; Katherine E Maturen; Stephanie Nougaret; Liina Poder; Gaiane M Rauch; Caroline Reinhold; Evis Sala; Isabelle Thomassin-Naggara; Herbert Alberto Vargas; Aradhana Venkatesan; Olivera Nikolic; Andrea G Rockall
Journal:  Eur Radiol       Date:  2021-11-30       Impact factor: 7.034

Review 2.  Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.

Authors:  Michail N Mavros; Dimitrios Moris; Paul J Karanicolas; Matthew H G Katz; Eileen M O'Reilly; Timothy M Pawlik
Journal:  JAMA Surg       Date:  2021-07-01       Impact factor: 14.766

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.